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Abstract Connective tissue growth factor (CTGF, CCN2)
is overexpressed in pancreatic cancer. We mapped the
minimal CCN2 promoter active in PANC-1 cells, a human
pancreatic cancer cell line. Within this region, Sp1, BCE-1
and Ets elements were important for the activity of the
CCN2 promoter. Constitutive hyperactivated ras is a
hallmark of cancers, including that of the pancreas. Treatment
of PANC-1 cells with the MEK inhibitor U0126 or the Sp1
inhibitor mithramycin reduced CCN2 mRNA and promoter
activity. Mutation of the BCE-1, but not Sp1 or Ets, site
abolished the responsiveness of the CCN2 promoter to
U0126. Overexpressing constitutively active MEK1 or ras
activated CCN2 promoter activity. Thus CCN2 is likely to act
downstream of ras in PANC-1 cells. CCN2 is overexpressed
in cancer cells. Activated ras/MEK/ERK is a hallmark of
cancer, and we have shown that the elevated CCN2 expression
in pancreatic cancer cells is dependent on this pathway.
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Introduction
Pancreatic cancer is currently the fourth leading cause of
cancer deaths in North America, with a median survival rate
of 6.4 months (Aikawa et al. 2006). Previous studies have
shown that pancreatic tumour cells have 59 times the
normal amount of connective tissue growth factor (CTGF/
CCN2; Wenger et al. 1999). CCN2 transcript levels are
proportional to the severity of pancreatic cancer (Wenger
et al. 1999; Hartel et al. 2004). CCN2 is a protein found in
the extracellular matrix (ECM) and functions as a modifier
of adhesive signalling in response to ECM and cytokines
(Chen et al. 2004; Shi-wen et al. 2006). CCN2 acts through
integrins and heparin-sulphate containing proteoglycans
influencing cell growth, apoptosis, migration and ECM
remodelling and deposition (Leask and Abraham 2006).
CCN2 promotes angiogenesis in vivo and in vitro (Babic
et al. 1999). Loss of CCN2 expression in embryonic
mesenchymal cells results in diminished cell migration
and adhesion, and reduction in pro-angiogenic and pro-
fibrotic gene expression (Chen et al. 2004; Kennedy et al.
2007). Previous studies have shown that application of an
antibody specific to CCN2 resulted in decreased tumour
volume, metastasis and angiogenesis (Aikawa et al. 2006).
CCN2 expression is controlled primarily at the tran-
scriptional level; therefore elements in its promoter are
likely to contribute to its overexpression in pancreatic
cancer (Blom et al. 2001). However, it is unknown which
cis-acting elements are responsible. Previously, we have
analysed the regions in the CCN2 promoter required for its
induction in response to TGFβ and endothelin-1 in normal
fibroblasts and mesangial cells, and its constitutively
elevated expression in fibrotic scleroderma fibroblasts
(Abraham et al. 2000; Holmes et al. 2001, 2003; Leask
et al. 2003; van Beek et al. 2006). CCN2 induction in
response to TGFβ in fibroblasts and mesangial cells requires
Smad 3 and Ets-1 and also requires ras/MEK/ERK (Holmes et
al. 2001; Stratton et al. 2002; Chen et al. 2002; Leask et al.
2003; van Beek et al. 2006). In addition, a basal control
element (BCE-1) and Sp1 contribute to basal activity of the
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CCN2 minimal promoter and the elevated CCN2 promoter
activity in scleroderma (Holmes et al. 2001, ).
Although CCN2 appears important in pancreatic cancer
progression, a mechanism for its overexpression in this
disease has yet to be proposed. Thus, we identified the
minimal CCN2 promoter active in PANC-1 pancreatic
cancer cells, and probed the cis-acting sequences and
signalling cascades required for its activity.
Materials and methods
Materials PANC-1 cells were obtained from Christopher Pin
(University of Western Ontario). High glucose Dulbecco’s
modified Eagle’s medium (DMEM), trypsin-EDTA, fetal
bovine serum (FBS), antibiotic/antimycotic solution were all
obtained from Invitrogen (Burlington, Ontario).
Cell cultures, transfections and DNA constructs PANC-1
cells were o cultured in high glucose DMEM (Invitrogen,
Burlington, Ontario). All media was supplemented with
10% FBS and 1% antibiotic/antimycotic solution. For
media assays, PANC-1 cells were plated at a density of
25,000 cells/well in a 24 well plate. Cells were allowed to
grow for 24 h at 37°C. Cells were then transfected with
Fugene (Roche, Indianapolis, IN, USA) at a ratio of 3:25 μl
DMEM per well. Cells were transfected with plasmids
containing a CCN2 promoter fused to a secreted alkaline
phosphatase (SEAP) reporter gene. Cells were transfected
with 2 μg of CTGF-SEAP constructs that were contained
either −244, −166 or −86 to +17 region of the CCN2
promoter, or had a point mutation to either the Smad, Ets,
BCE-1 or Sp1 site (Abraham et al. 2000; Holmes et al.
2001, 2003; Leask et al. 2003). When indicated, cells were
transfected with empty expression vector, or expression
vectors encoding constitutively activated ras or MEK1
(Upstate). To control for transfection efficiency cells were
transfected with 0.4 μg of a cytomegalovirus (CMV)
promoter – β-galactosidase (β-gal) reporter gene (Clontech,
Palo Alto, CA, USA) construct. Cells were allowed to grow
for 48 h in 37°C. Inhibitors (when used) were added 24 h
after transfection. Promoter assays were performed with a
Phospha-Light kit (Applied Biosystems, Foster City, CA,
USA) according to manufacturer’s protocol and SEAP
reporter expression was adjusted for differences in β-
galactosidase expression as determined by a Galacto-star kit
(Applied Biosystems) according to manufacturer’s protocol.
Data was expressed as average values +/− standard
deviation of at least three replicates and at least two
independent trials. Measurement of SEAP levels were
obtained from an LMax II 384 luminometer (Molecular
Devices, Sunnyvale CA, USA) and SoftMax Pro 4.7.1
(Molecular Devices, Sunnyvale CA, USA). Samples were
run in quadruplicate, and levels were measured in relative
light units and were standardized to control values from
â-gal. Statistical tests were done using one-way ANOVA
and Tukey’s post hoc test on GraphPad.
Real time RT-PCR PANC-1 cells were grown in high
glucose DMEM. All media was supplemented with 10%
FBS and 1% antibiotic/antimycotic. Cells were plated onto a
six well plate at a density of 60,000 cells/well and were allowed
to grow for 24 h at 37°C. Cells were then treated with focal
adhesion kinase/src inhibitor (FAK/SRC) PP2, p38 MAP
Kinase inhibitor SB203580, MEK/ERK inhibitor U0126,
phosphatidyl-inositol triphosphate (PIP3) inhibitor LY294002,
Fig. 1 Identification of the CCN2 minimal promoter in PANC-1
Cells. a Diagram of the CCN2 minimal promoter, including known
functional transcription factor elements. The bases mutated in each
construct are shown below. Wt wild-type sequence, mut mutated
sequence. b PANC-1 cells were co-transfected for 48 h with CCN2
promoter-SEAP reporter test constructs and a CMV promoter-β-
Galactosidase construct. Plasmids had regions of the CCN2 promoter
starting at −244, −166 or −86 to +17. Values were expressed in
relative light units and normalized with β-galactosidase. Values are
mean of four replicates, +/− standard deviation from three separate
experiments. Asterisk indicates significantly different from −244/+17
construct, P<0.01
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protein kinase C (PKC) inhibitor bisindolmaleimide I (all
Calbiochem, La Jolla, CA, USA), or Sp1 inhibitor Mithra-
mycin (Sigma, St Louis, MO, USA) at a concentration of
10 μM, except mithramycin which was used at 100 nM and
SB203580 which was used at 30 μM. RNA was harvested
using the Qiashredder and RNeasy kit (Qiagen) and used for
real-time RT-PCR. Twenty-five nanograms of RNA was
reverse transcribed and amplified using TaqMan Assays on
Demand (Applied Biosystems) in a 15 μl reaction containing
primers for TaqMan Human CTGF (Applied Biosystems)
and 6-carboxyfluroscein labelled TaqMan MGB probe.
Reverse transcriptase qPCR Mastermix (Eurogenetics) was
added to samples and the ABI Prism 7900 HT sequence
detector (Perkin-Elmer-Cetus, Vaudreuil, QC) was used
according to manufacturer’s instructions to detect amplified
sequences. Samples were run in triplicate, transcripts were
measured in picograms and expression values were standard-
ized to control values from GAPDH primers. Statistical
analysis was done using one way ANOVA and Tukey’s post
hoc test on GraphPad.
Results
Ets, BCE-1 and Sp1, but not Smad, sites contribute
to CCN2 minimal promoter activity in PANC-1 cells
To determine which promoter elements contributed to CCN2
overexpression in PANC-1 cells, PANC-1 cells were trans-
fected with CCN2 promoter-SEAP reporter constructs con-
taining regions spanning between −244, −166 or −86 to +17.
The −244 to +17 promoter fragment contains the previ-
ously identified CCN2 minimal promoter region (Leask et
al. 2003) and Smad, BCE-1, Ets-1 and Sp1 sites (Fig. 1a).
Conversely, the −166 promoter contained only BCE-1,
Ets-1 and Sp1 and the −86 promoter contained only the
Sp1 region (Leask et al. 2003). Although all three
promoter fragments possessed abundant activity, only
Fig. 2 Ets, BCE-1 and Sp1, but not Smad, sites contribute to CTGF
promoter activity in PANC-1 cells. PANC-1 cells were co-transfected
for 48 h with CCN2 promoter-SEAP reporter test constructs and a
CMV promoter-β-galactosidase construct. Plasmids contained either
the wild-type CCN2 promoter or otherwise identical promoters with
mutations in Smad, Ets, BCE-1 or Sp1 sites and expression values
were measured in relative light units. Expression values were
normalized with β-galactosidase. The experiment was repeated
performed twice. Values were expressed in relative light units and
normalized with β-Galactosidase. Values are mean of four replicates, +/−
standard deviation from three separate experiments. *significantly
different from −244/+17 construct, P<0.05. Note that mutation of Ets,
BCE-1 and Sp1 sites decreased CCN2 promoter activity, whereas
mutation of the Smad element increased CCN2 promoter activity
Fig. 3 Inhibiting MEK and Sp1 potently decreased
CCN2 mRNA and protein expression. a Cells were
incubated for 24 h with inhibitors of signal trans-
duction cascades. RNA was harvested and subjected
to real time RT-PCR and was normalised with
GAPDH. The experiment was performed twice.
Columns, mean of separate experiments performed
in triplicate; bars, SE (asterisk indicates significantly
reduced CCN2 mRNA due to inhibitor, P<0.001).
Inhibitors used were: 10 μM bisindolmaleimide I
(PKC), 10 μM LY294002 (LY), 30 μM SB203580
(SB), 10 μM PP2, 10 μM U0126 or 100 nM
mithramycin. b Cells were incubated for 24 h with
inhibitors of signal transduction cascades. Protein
was harvested and subjected to Western blot analyses
with anti-CCN2 and anti-β-actin antibodies
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deleting −166 to −86 had a statistically significant impact
on basal CCN2 promoter activity in PANC-1 cells (Fig. 1).
To further investigate which specific promoter elements
were involved in CTGF overexpression, PANC-1 cells were
transfected with CCN2 promoter-SEAP reporter constructs
containing a wild-type promoter sequence, or point muta-
tions to either the Smad, BCE-1, Ets-1 or Sp1 sites.
Consistent with our deletion analysis showing removal of
the Smad element had no significant impact on activity of
the CCN2 minimal promoter, point mutation to the Smad
site resulted in no significant decrease in CCN2 promoter
activity; indeed, mutating the Smad element seemed to
increase basal CCN2 promoter activity in PANC-1 cells.
Conversely, mutating BCE-1, Ets, or Sp1 sites resulted in
significant decreases in promoter activity (Fig. 2). More-
over, treatment of PANC-1 cells with the Sp1 inhibitor
mithramycin reduced expression of CCN2 mRNA and
protein (Fig. 3a, b) and activity of the CCN2 minimal
promoter (Fig. 4). These results suggest that the BCE-1, Ets
and Sp1, but not Smad element, are implicated in CCN2
overexpression in PANC-1 cells.
Inhibiting MEK potently decreases CCN2 mRNA
expression in PANC-1 cells
In order to determine which signaling pathways were most
important in CCN2 overexpression in pancreatic cancer,
PANC-1 cells were treated with inhibitors to p38 (SB
203580), MEK/ERK (U0126), FAK/SRC (PP2), PI3 kinase
(LY 294002) or PKC (bisindolmaleimide I) at concentra-
tions previously demonstrated to selectively block action of
the respective targets. Although real-time RT-PCR analysis
determined that while inhibition of p38, FAK/SRC, PI3
kinase and PKC resulted in modest (∼50–60%) reductions
in CCN2 mRNA, inhibition of MEK resulted in a potent
(∼90%) reduction of CCN2 mRNA expression (Fig. 3).
Based on these data showing that inhibition of MEK
strongly reduced CCN2 mRNA in PANC-1 cells, and
Fig. 5 MEK acts through BCE-1 in PANC-1 cells. Cells were
incubated for 48 hours with a CCN2 promoter-SEAP reporter
construct that was either full length or had mutations to the BCE-1,
Ets or Sp1 region, as well as with a CMV-β-galactosidase construct.
Half were then incubated for 24 h with 10 μmol ml−1 media−1 of
U0126. Experiments were performed twice, with four replicates per
trial. Results were essentially identical in each experiment. Expression
values were measured in relative light units and are displayed as a
percentage of the control untreated wild-type values. (asterisk
indicates significantly reduced activity of the CCN2 promoter as
compared to U0126 treatment, P<0.01). Standard deviation values
were all below 10%
Fig. 4 MEK and Sp1 significantly contribute to CTGF promoter
activity. a PANC-1 cells were transfected with a CCN2 full length
promoter-SEAP construct and a CMV promoter-β-galactosidase
construct. Twenty-four hours after treatment with constructs, the cells
were treated for 24 h with mithramycin or U0126 inhibitors.
Experiments were performed twice. Expression values were normal-
ised with β-galactosidase. Columns: means of four replicates; bars,
SE, (asterisk indicates significantly reduced CTGF expression due to
inhibitor, P<0.01, double asterisks indicate significantly reduced
CTGF expression due to inhibitor, P<0.001). b PANC-1 cells were
transfected with a CCN2 full length promoter-SEAP construct and a
CMV promoter-β-galactosidase construct. Cells were co-transfected
with empty expression vector (EMPTY), or expression vector
encoding constitutively active ras (caras) or constitutively active
MEK1 (caMEK1). Cells were assayed 48 h after transfection.
Experiments were performed twice. Values were expressed in relative
light units and normalized with β-galactosidase. Values are mean of
four replicates, +/− standard deviation from three separate experi-
ments. Asterisk indicates significantly different from −244/+17
construct, P<0.01
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previous observations that activated ras/MEK/ERK is a key,
characteristic feature of cancer cells (Yamamoto et al.
1999), we further probed the contribution of ras/MEK/ERK
in regulation of CCN2. First, U0126 reduced CCN2 protein
expression in PANC-1 cells (Fig. 3). Second, PANC-1 cells
were transfected with CCN2 promoter-SEAP reporter
constructs, and then treated with U0126. Treatment with
U0126 resulted in a significant decrease in CCN2 promoter
activity as compared to controls (Fig. 4a). Moreover,
overexpression of either activated ras or activated MEK1
increased CCN2 promoter activity (Fig. 4b).
MEK Acts through BCE-1
AsMEK appeared to be important in the activity of the CCN2
promoter in PANC-1 cells, we wanted to further investigate
the mechanism by which MEK was influencing CCN2
expression. In order to determine whether MEK was acting
through the BCE-1, Ets or Sp1 element, cells were transfected
with CCN2 promoter-SEAP reporter constructs containing
mutations in these sites. Cells in each treatment group were
then further split into two separate groups: a control group and
a group that was incubated with the MEK inhibitor for 24 h.
Only mutation of the BCE-1 site abolished the sensitivity of
the CCN2 promoter to MEK inhibition (Fig. 5). Collectively,
these data suggest that ras/MEK/ERK induces the CCN2
promoter in PANC-1 cells through the BCE-1 element.
Discussion
Previous studies have found that CCN2 is abundant in
pancreatic cancer, and that this overexpression may be related
to the cancer progression (Aikawa et al. 2006; Dornhofer et
al. 2006). However, until this report there was no proposed
mechanism for CCN2 overexpression in pancreatic cancer.
As there is currently no sufficient treatment for pancreatic
cancer, obtaining a greater understanding of the mechanisms
underlying pancreatic cancer progression, such as the
mechanism underlying the overexpression of CCN2, is
crucial in order to identify novel potential drug targets.
It has been shown previously in fibroblasts and
mesenchymal cells that CCN2 is induced by TGF-β acting
through the Smad 3/4 pathway and an Ets element (Leask et
al. 2003). However, in this report we showed that the
increased basal activity of the CCN2 promoter in PANC-1
was not diminished by mutation or deletion of the Smad
element. Conversely, mutation of the Ets, Sp1 or BCE-1
elements reduced the activity of the CCN2 promoter in
PANC-1 cells. In addition, the Sp1 inhibitor mithramycin
reduced CCN2 mRNA and protein expression in PANC-1
cells. These data are similar to results obtained in
scleroderma fibroblasts in which CCN2 overexpression
was TGFβ/Smad-independent and Sp1/BCE-1-dependent
(Holmes et al. 2001, 2003; Chen et al. 2006). These results
strongly support the notion that TGFβ is not required under
situations when CCN2 is constitutively expressed. Previ-
ously, we have shown that the Ras/MEK/ERK pathway
regulates CCN2 levels in response to TGF-β and ET-1
(Chen et al. 2002; Leask et al. 2003; Shi-wen et al. 2004).
Indeed, it is interesting to note that antagonizing receptors
for either TGFβ or ET-1 was not effective at blocking
CCN2 expression in PANC-1 cells (data not shown), in
spite of the fact that ET-1 induces the CCN2 promoter via
BCE-1 and ras/MEK/ERK in lung fibroblasts (Shi-wen et
al. 2004). However, this is the first report examining the
mechanism underlying MEK/ERK-dependent regulation of
CCN2 expression. The identity of the transcription factor(s)
binding to BCE-1, an element initially identified by
Grotendorst et al. (1996), has not thus far been identified.
The involvement of ras/MEK/ERK in constitutively
elevated CCN2 expression in pathological states has not
until now been demonstrated. It is interesting to note that κ-
Ras, a member of the ras family of GTP-binding proteins,
has been found to be mutated in pancreatic cancer,
decreasing its GTP hydrolysis, causing it to be constitu-
tively active, constantly activating the MEK/ERK pathway,
leading to extensive cell proliferation (Hezel et al. 2006) in
a fashion that is likely to be independent of growth factors
and cytokines. This observation is consistent with the fact
that antagonising TGFβ or ET-1 receptors did not affect the
CCN2 promoter activity in PANC-1 cells. Thus, CCN2 is
likely to be operating downstream of hyperactive ras in
promoting oncogenesis. Previous studies using an anti-
CCN2 antibody have suggested that anti-CCN2 strategies
may be useful in combating pancreatic cancer (Aikawa et
al. 2006; Dornhofer et al. 2006); however, in these studies
no mechanistic insight underlying the effect of the antibody
was provided. Exogenous CCN2 has been shown to
promote angiogenesis, proliferation and migration in a
context-specific fashion (Leask and Abraham 2006). How-
ever, the effect of endogenous CCN2 in cancer, including
that of the pancreas is unclear, and awaits further studies.
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